Síndrome cardiorrenal Andrés Buitrago Maldonado

El síndrome cardiorrenal (SCR) es una situación de afectación de

ambos órganos (Corazón y riñón) en que se potencian sus efectos

deletéreos de forma que el daño renal y el miocárdico progresan de

forma acelerada y retroalimentándose

Sociedad Española de Nefrología; Nefrología (2008) Supl. 3, 29-32

International Journal of Nephrology Volume 2011, Article ID 920195, 11 pages

CRS Type 1Pathophysiological interactions between heart and kidney in type 1 cardiorenal syndrome (CRS) or “acute CRS” (abrupt worsening of cardiac function, e.g., acute cardiogenic shock or acute decompensation of chronic heart failure) leading to kidney injury. ACE = angiotensin-converting enzyme; ANP = atrial natriuretic peptide; BNP = B-type (Brain) natriuretic peptide; CO = cardiac output; GFR = glomerular filtration rate; KIM = kidney injury molecule; N-GAL = neutrophil gelatinase-associated lipocalin; RAA = renin angiotensin aldosterone.

Figure 2 CRS Type 2 Pathophysiological interactions between heart and kidney in type 2 cardiorenal syndrome (CRS) or “chronic CRS” (chronic abnormalities in cardiac function, e.g., chronic heart failure) causing progressive chronic kidney disease (CKD). F...

CRS Type 3Pathophysiological interactions between heart and kidney in type 3 CRS or “acute renocardiac syndrome” (abrupt worsening of renal function, e.g., acute kidney failure or glomerulonephritis) causing acute cardiac disorder (e.g., heart failure, arrhythmia, pulmonary edema). MPO = myeloperoxidase; other abbreviations as in Figure 1. 

CRS Type4 Pathophysiological interactions between heart and kidney in type 4 cardiorenal syndrome (CRS) or “chronic renocardiac syndrome” (chronic kidney disease [CKD], e.g., chronic glomerular disease, contributing to decreased cardiac function, cardiac hypertrophy, or increased risk of adverse cardiovascular events). BMI = body mass index; EPO = erythropoietin; LDL = low-density lipoprotein.

CRS Type 5 Pathophysiological interactions between heart and kidney in type 5 cardiorenal syndrome (CRS) or “secondary CRS” (systemic condition, e.g., diabetes mellitus, sepsis, causing both cardiac and renal dysfunction). LPS = lipopolysaccharide (endotoxin); RVR = renal vascular resistance. 

Bibliografía Journal of the American College of Cardiology Vol. 52, No. 19, 2008 ©

2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.07.051

The Cardiorenal Syndrome: A Review; B. N. Shah and K. Greaves; International Journal of Nephrology Volume 2011, Article ID 920195, 11 pages doi:10.4061/2011/920195

Epidemiology of cardio-renal syndromes: workgroup statements fromthe 7th ADQI Consensus Conference; Sean M. Bagshaw, et al; Nephrol Dial Transplant (2010) 25: 1406–1416 doi: 10.1093/ndt/gfq066.

Síndrome cardio-renal: diagnóstico y tratamiento; Segovia, E. Medwave 2011 May;11(05):e5028 doi: 10.5867/medwave.2011.05.5028

Gracias